Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C

Gut

Volumn 64, Issue 8, 2015, Pages 1277-1288

  Miguel, Ramón San ^a   Gimeno Ballester, Vicente ^b   Blázquez, Antonio ^c   Mar, Javier ^d  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c Agencia Española de Medicamentos y Productos Sanitarios ^*  (Spain)

^d Hospital Alto Deba   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ARTICLE; CHRONIC HEPATITIS C; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; GENOTYPE; HEALTH CARE QUALITY; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; TIME TO TREATMENT; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HEPATITIS C, CHRONIC; MIDDLE AGED; PROBABILITY; SPAIN; STATISTICS AND NUMERICAL DATA;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; MARKOV CHAINS; MIDDLE AGED; SPAIN; URIDINE MONOPHOSPHATE;

EID: 84940377882     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307772     Document Type: Article

References (58)

1. European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32 (suppl 1):2-8.
2. Alter MJ, Kruszon-Moran D, Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
3. Ghany MG, Nelson DR, Strader D.B., et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
4. Wong JB, Bennett WG, Koff R.S., et al. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998; 280:2088-93.
5. van de Laar M, Veldhuijzen I, Hahn S. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: European Centre for Disease Prevention and Control, 2010:56.
6. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
7. Jacobson IM, McHutchison JG, Dusheiko G, et al Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
8. Bacon BR, Gordon SC, Lawitz E, et al Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
9. Zeuzem S, Andreone P, Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
10. Jacobson IM, Gordon SC, Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-77.
11. Lawitz E, Mangia A, Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
12. Kowdley KV, Lawitz E, Crespo I., et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381:2100-7.
13. San Miguel R., Gimeno-Ballester V, Mar J. Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Rev Pharmacoecon Outcomes Res 2014; 14:387-402.
14. Gold M, Siegel J, Russell L., eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
15. Drummond MF, O'Brien B, Stoddart GL, et al Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2003.
16. European Medicines Agency. Sovaldi product information. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002798/WC500160597.pdf (accessed 3 May 2014).
17. Sacristan JA, Oliva J, del Llano J, et al. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002; 4:334-43.
18. Lalezari JP, Nelson DR, Hyland R.H., et al. Once-Daily Sofosbuvir Plus Ribavirin Given for 12 or 24 Weeks in Treatment-Naïve Patients With HCV Infection: the QUANTUM Study. 48th Annual Meeting of the European Association for the Study of the Liver, 24-28 April 2013, Amsterdam, The Netherlands. 2013.
19. Osinusi A, Meissner EG, Lee Y-J, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310:804-11.
20. Fried MW, Shiffman ML, Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
21. Gane EJ, Stedman CA, Hyland R.H., et al. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study. J Hepatol 2013; 58:S6-7.
22. Lalezari JP, Lawitz EJ, Rodriguez-Torres M, et al. Once daily PSI 7977 PegIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with G2/G3. J Hepatol 2011; 54:s28.
23. Zeuzem S, Dusheiko G, Salupere R. Sofosbuvir+ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial [abstract no. 1085]. Hepatology 2013; 58:733A-4A.
24. Poynard T, Colombo M, Bruix J., et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136:1618-28. e2.
25. Lawitz E, Poordad F, Brainard D.M., et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology 2013; 58:1380A.
26. Osakidetza. Comité de evaluación de nuevos medicamentos de uso Hospitalario: Telaprevir (Incivo®). http://www.osakidetza.euskadi.net/r85-pkcevi03/es/contenidos/informacion/cevime-ambito-hospitalario/es-cevime/adjuntos/telaprevir-informe.pdf (accessed 1 Apr 2014).
27. Osakidetza. Comité de evaluación de nuevos medicamentos de uso Hospitalario: Boceprevir (Victrelis®). http://www.osakidetza.euskadi.net/r85-pkcevi03/eu/contenidos/informacion/cevime-ambito-hospitalario/eu-miez/adjuntos/boceprevir-informe.pdf (accessed 1 Apr 2014).
28. Townsend R, McEwan P, Kim R., et al. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 2011; 14:1068-77.
29. Cardoso A-C, Moucari R., Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52:652-7.
30. Veldt BJ, Heathcote EJ, Wedemeyer H, et al Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677-84.
31. Fattovich G, Giustina G, Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-72.
32. Buti M, Casado MA, Fosbrook L, et al Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha. Gastroenterol Hepatol 1998; 21:161-8.
33. Buti M, Casado MA, Fosbrook L, et al Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics 2005; 23:1043-55.
34. San Miguel R., Mar J, Cabasés JM, et al. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. Aliment Pharmacol Ther 2003; 17:765-73.
35. Blázquez-Pérez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. Pharmacoeconomics 2013; 31:919-31.
36. Grieve R, Roberts J, Wright M., et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55:1332-8.
37. Cure S, Bianic F, Gavart S., et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ 2014; 17:65-76.
38. Cure S, Bianic F, Gavart S., et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. J Med Econ 2014; 17:77-87.
39. Siebert U, Sroczynski G, Wasem J., et al. Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Eur J Health Econ 2005; 6:112-23.
40. Sonnenberg FA, Beck JR Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322-38.
41. Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40:823-30.
42. Salomon JA, Weinstein MC, Hammitt J.K., et al. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002; 156:761-73.
43. Organización Nacional de Transplantes. Registro español de transplante hepático. Memoria de resultados, 2010. http://www.ont.es/infesp/Registros/MEMORIA%20RETH%202010.pdf (accessed 1 Apr 2014).
44. Bennett WG, Inoue Y, Beck J.R., et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127:855-65.
45. Camma C, Petta S, Cabibbo G., et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol 2013; 59:658-66.
46. Camma C, Petta S, Enea M., et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56:850-60.
47. Chan K, Lai MN, Groessl E.J., et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic hcv genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 2013; 11:1503-10.
48. Chhatwal J, Ferrante SA, Brass C, et al Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health 2013; 16:973-86.
49. Briggs AH, Claxton K, Sculpher MJ Decision modelling for health economic evaluation. Oxford university press, 2006.
50. O'Brien B.J., Drummond MF, Labelle R.J., et al. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32:150-63.
51. Wright M, Grieve R, Roberts J., et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10:1-113, iii.
52. Briggs AH, Goeree R, Blackhouse G., et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22:290-308.
53. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. http://www.gov.uk/government/uploads/system/uploads/attachment-data/file/191504/NICE-guide-to-the-methods-of-technology-appraisal.pdf (accessed 15 Jul 2014).
54. Husereau D, Drummond M, Petrou S., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013; 16:231-50.
55. Deuffic-Burban S., Schwarzinger M, Obach D., et al. Should we await FN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol 2014; 61:7-14.
56. Tice JA, Ollendorf DA, Pearson SD The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection. 2014. http://www.ctaf.org/sites/default/files/assessments/CTAF-Hep-C-Apr14-final.pdf (accessed 3 May 2014).
57. The Editorial Board. How Much Should Hepatitis C Treatment Cost? The New York Times. 2014. http://www.nytimes.com/2014/03/16/opinion/sunday/how-much-should-hepatitis-c-treatment-cost.html (accessed 3 May 2014).
58. Drugs for Hepatitis C. The New York Times. 2014. http://www.nytimes.com/2014/03/26/opinion/drugs-for-hepatitis-c.html (accessed 3 May 2014).